Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

Neurology

Volumn 68, Issue 4, 2007, Pages 272-276

  Watts, R L ^a,g   Jankovic, J ^b   Waters, C ^c   Rajput, A ^d   Boroojerdi, B ^e   Rao, J ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e Schwarz Pharma AG   (Germany)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; INSOMNIA; LEG PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; PAIN; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SOMNOLENCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, CUTANEOUS; AGED; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES; TIME FACTORS;

EID: 33846438955     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000252355.79284.22     Document Type: Article

References (20)

1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
2. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;Jul 36:27-31.
3. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004;62(suppl 1):S56-S63.
4. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20(suppl 11):S11-S16.
5. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
6. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23:34-44.
7. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
8. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
9. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-1062.
10. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 2003;61(suppl 3):S12-S16.
11. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
12. Watts RL, Wendt J, Nausieda PL, Boroojerdi B, Poole KH, Sommerville KW. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004;19(suppl 9):258.
13. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
14. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol 1998;55:1211-1216.
15. Vaillant L, Biette S, Machet L, Constans T, Monpere C. Skin acceptance of transcutaneous nitroglycerin patches: a prospective study of 33 patients. Contact Dermatitis 1990;23:142-145.
16. Eichelberg D, Stolze P, Block M, Buchkremer G. Contact allergies induced by TTS-treatment. Methods Find Exp Clin Pharmacol 1989;11:223-225.
17. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998;15:168-175.
18. Groth H, Vetter H, Knusel J, Foerster E, Siegenthaler W, Vetter W. Transdermal clonidine application: long-term results in essential hypertension. Klin Wochenschr 1984;62:925-930.
19. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
20. Reynolds NA, Wellington K, Easthope SE. Rotigotine: in Parkinson's disease. CNS Drugs 2005;19:973-981.